



Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study

Marie Gérardin, Morgane Rousselet, Marie-Laure Couec, Agathe Masseau, Christelle Chantalat, Françoise Driss, Corinne Guitton, Karima Debbache, Elena Foïs, Frédéric Galacteros, et al.

► To cite this version:

Marie Gérardin, Morgane Rousselet, Marie-Laure Couec, Agathe Masseau, Christelle Chantalat, et al.. Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study. Orphanet Journal of Rare Diseases, 2024, 19 (124), <10.1186/s13023-024-03133-w>. <hal-04546154>

HAL Id: hal-04546154

<https://hal.science/hal-04546154v1>

Submitted on 15 Apr 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

RESEARCH

Open Access



Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study

Marie Gérardin¹, Morgane Rousselet^{1,2,3}, Marie-Laure Couec⁴, Agathe Masseau⁵, PHEDRE Group⁶, Aurélie Aquizerate¹, Nicolas Authier⁷, Sylvie Deheul⁸, Anne Roussin⁹, Joelle Micallef¹⁰, Samira Djezzar¹¹, French Addictovigilance Network (FAN)¹², Fanny Feuillet^{13,3}, Pascale Jolliet^{1,3}, Marie Grall-Bronnec^{2,3} and Caroline Victorri-Vigneau^{1,3*}

Abstract

Background In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients.

Results A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were looking for an analgesic effect, but 68% of patients were also looking for other effects. The independent risks factors associated with at least one SUD criterion were: the feeling of effects different from the expected therapeutic effects of EMONO, at least one hospitalization for vaso occlusive crisis in the past 12 months and the presence of a SUD for at least one other analgesic drug.

Conclusions The use of EMONO was not problematic for the majority of patients. Manifestations of SUD that led to tensions with healthcare teams should alert and lead to an evaluation, to distinguish a true addiction from a pseudoaddiction which may be linked to an insufficient analgesic treatment related to an underestimation of pain in SCD patients.

Trial registration: Clinical Trials, NCT02580565. Registered 16 October 2015, <https://clinicaltrials.gov/>

Keywords Pain, Substance use disorder, Pseudoaddiction, Sickle cell disease, Nitrous oxide

*Correspondence:
Caroline Victorri-Vigneau
caroline.vigneau@chu-nantes.fr
Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Nitrous oxide: a gas with two sides

Nitrous oxide (N_2O) has been used in medical practice for many years due to its analgesic and anxiolytic properties [1]. It is also used as a food additive, and it is currently one of the most popular substances used by young people for its euphoric effects. The mechanism of N_2O is still not fully known [2]; it interacts in particular with opioidergic, GABAergic, dopaminergic and glutamatergic systems. N_2O is a substance monitored in many countries because of the misuse of cartridges for whipped cream. Dependence on and tolerance to the effects of N_2O have been demonstrated [3]. Moreover, numerous cases of N_2O abuse and subsequent adverse effects have been reported in the literature [4–10].

In medical practice, it is used worldwide in a gas mixture with oxygen in the indication of short-term analgesia for painful procedures or for mild to moderate pain in adults and children. An equimolar mixture of oxygen and nitrous oxide (EMONO) has been a marketing authority in France since 2001. Because of the risk of abuse/dependence, it is subject to a risk management plan (RMP) monitored by the national French Addictovigilance Network (FAN) under the responsibility of the Nantes Addictovigilance Centre. Reports of the RMP highlighted cases of addiction or adverse effects following very extensive and prolonged use of the gas [11]. These cases involved patients in a serious medical situation, requiring repeated use of EMONO.

SCD patients: a vulnerable population

SCD is an inherited red blood cell disorder caused by the presence of abnormal haemoglobin, called haemoglobin S (HbS), which often leads to complications, including vaso-occlusion, that result in tissue ischaemia causing acute, severe pain episodes [12, 13]. In cases of hospitalization for vaso-occlusive crisis (VOC), EMONO is used for the rapid management of pain in combination with morphine in children and adolescents [14, 15]. Among SCD patients, pain is subject to significant inter-individual and intraindividual variability with respect to the severity, site and duration of the pain episode, which leads to difficulties in management among patients and health care professionals [14, 16]. However, if the profile of SCD patients (young people, recurrent pain, psychiatric comorbidities, exposure to analgesic and psychotropic drugs, etc.) can represent a risk factor for addiction, poor pain management can expose patients to the risk of pseudoaddiction. Addiction is characterized by craving for drug or positive reward, dysfunctional emotional response, failure to recognize significant problems affecting behaviour and relationships, inability to consistently abstain, and impairment in control of behaviour [17].

Pseudoaddiction (defined as a constant fear of being in pain, hypervigilance, usually resolving with pain resolution) [17] occurs when patients attempt to obtain a higher analgesic dose to relieve pain. This behaviour could be interpreted by medical staff as being compatible with substance use disorders (SUDs), but in pseudoaddiction, analgesic-seeking behaviour stops when the pain is treated effectively and does not persist after pain relief has been achieved [18]. The major risk is that these patients receive fewer analgesics; therefore, treatment is not optimal [19–21].

SCD and nitrous oxide: Addiction or pseudoaddiction?

Currently, there are few data available on this concern, and no studies have been carried out in patients with SCD. Regrettably, potential SUD with EMONO is an issue for patient treatment strategies, and the need for specific evaluation is supported by physicians working on SCD.

The PHEDRE study (Pharmacodépendance et DREpanocytose—drug dependence and SCD) is the first national study aimed at evaluating the use of EMONO in patients with SCD.

Methods

Study design

The PHEDRE study protocol was previously described in a publication, freely available online [22]. It was a national, observational, and transversal study based on an interview carried out by the Nantes Addictovigilance Centre and funded by a Grant from the French National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament et des produits de santé – ANSM). It was monitored by a pluridisciplinary steering committee (pharmacologists, psychiatrists specializing in addiction, biostatisticians, and physicians specializing in SCD). This study was approved by the local health ethics committee, the CCTIRS (Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé) and the CNIL (Commission Nationale de l'Informatique et des Libertés). The study is registered as NCT02580565. All participants provided written informed consent (and legal representation for patients under 18 years old) in accordance with the Declaration of Helsinki.

Patients

In France, patients with SCD can benefit from a follow-up in a Reference Centre or Special Centre for Children and Adults (RSCCA). To be eligible for the PHEDRE study, patients had to (1) have a SCD diagnosis confirmed by genetic testing, (2) be treated in an RSCCA, and (3) have given informed written consent.

Patients under guardianship (under tutelage or curatorship) and those without the general aptitude to participate in the study assessment (*i.e.*, not able to respond to the telephone interview) were not included in the study.

Study procedures

The patients were recruited by their physician when they came to the RSCCA for their routine follow-up between September 2015 and December 2017. The physician completed a form with the patient's medical data. Thereafter, patients were interviewed by phone by a trained interviewer. An ad hoc standardized heteroquestionnaire for phone interview was validated by the steering committee. Before starting phone interviews, the interviewer had a specific formation on SCD and pharmacodependence with members of the steering committee and received a notice with instructions on how to ask the questions according to the age of the interviewee and the substance used.

Data from the physician's form included demographic (sex, age) and clinical data (SCD genotype, hospitalizations for VOC in the past 12 months). Data from the

phone interview included socioeconomic data (occupational activity for majors, employment status of mother and father for minors) number of different analgesics used at home in the past 12 months, use of psychoactive medicines or drugs (other than analgesics) in the past 12 months (only for patients age 12 and over), effects sought and felt with EMONO, use of EMONO out of a painful context (*i.e.*, in the hospital but at a time when there was little or no pain) and assessment of SUD for EMONO and other analgesic drugs according to DSM 5 criteria [23].

To assess the effects of EMONO, felt or sought, patients were asked to answer “yes” or “no” to the following proposals: analgesia, sedation, anxiolysis, reduction of negative affects, gliding, well-being and other effects (specify). For the analysis, effects were grouped into categories as follows: “Therapeutic only” when the analgesic effect was the only or when it was associated with sedation and/or anxiolysis but with no other effect; “Gliding” when “high” effects were mentioned regardless of other effects; “Others” for patients who did not fit into either of the above two categories.




Fig. 1 SUD criteria positivity rate. *if there are missing data for some items, the number of patients concerned is mentioned below. DSM SUD criteria: Item 1 = Using more of a substance than planned, or using a substance for a longer interval than desired (missing data for 2 patients). Item 2 = Inability to cut down despite desire to do so (missing data for 2 patients). Item 3 = Spending substantial amount of the day obtaining, using, or recovering from substance use (missing data for 1 patient). Item 4 = Cravings or intense urges to use (missing data for 1 patient). Item 5 = Recurrent substance use may result in a failure to fulfill major role obligations at work, school, or home (missing data for 1 patient). Item 6 = Persistent usage despite persistent or recurrent social or interpersonal problems. Item 7 = Giving up or cutting back on important social, professional, or leisure activities because of use. Item 8 = Using in physically hazardous situations, or usage causing physical or mental harm. Item 9 = Persistent use despite the user's awareness that the substance is causing or at least worsening a physical or mental problem. Item 10 = Tolerance: needing to use increasing amounts of a substance to obtain its desired effects (missing data for 2 patients). Item 11 = Withdrawal: characteristic group of physical effects or symptoms that emerge as amount of substance in the body decreases (missing data for 2 patients) (N=339 patients*)

SUD was assessed using DSM 5 criteria [23] in relation to the context(s) of use: 1) when the drug was used for analgesic effects in a painful context and 2) when (if) the drug was used outside a painful context. According to the DSM 5, SUD was defined by meeting at least 2 of the 11 diagnostic criteria. Figure 1 (SUD criteria positivity rate) details SUD criteria. As a general estimate of severity, a “mild” SUD is suggested by the presence of two to three criteria, “moderate” by four to five criteria, and “severe” by six or more criteria.

Outcomes

The primary outcome was the prevalence of SUD for EMONO according to DSM 5 criteria in a painful context and out of a painful context (if applicable). The secondary outcomes addressed in this publication were the characterization of patients with one or more SUD criteria for EMONO and the identification of factors associated with the presence of these criteria. Indeed, even if only one criterion is present, it is important to identify patients at risk of addiction as early as possible. Other secondary objectives (assessment of prevalence and characterization of SUD for other analgesics) will be the subject of a separate publication.

Sample size

The aim was to include all patients who met the inclusion criteria in RSCCA who agreed to participate in the study. The study was proposed to the physicians of 79 RSCCA spread over the French territory (72 main centres and 7 annex centres). The total number of patients who could be included in France was thus estimated to be approximately 2000 people.

Statistical analysis

Continuous data are expressed as the mean (\pm SD), and categorical data are expressed as numbers and percentages. The primary outcome is expressed as a prevalence, including a confidence interval of 95% (95% CI). Patients with missing data that did not enable SUD evaluation were excluded from the analysis. Univariate analysis was conducted to determine the potential factors associated with the presence of at least one SUD criterion using the chi-square test or Student's *t* test as appropriate. Variables identified by univariate analysis with a cut-off at 0.20 were included in a multivariate logistic regression model, and backwards selection was applied. A Hosmer–Lemeshow test was used to test the calibration of the model. The final model is presented with the adjusted odds ratio (OR) and 95% CI.

Results

Descriptive analysis

Seventy-three RSCCA participated in the PHEDRE study in metropolitan France and overseas departments. A

total of 993 patients were included. Data for 121 patients could not be analysed (not reachable, refusal to answer, etc.), and 872 remained for analysis. Among them, 339 patients (39%) had used EMONO in the 12 months preceding the study. Their main characteristics are described in Table 1.

They were mainly female (57%) and had a mean age of 20.2 years. A total of 147 subjects were minors (43%), in most cases parents were employed (82% for father employment, 68% for mother employment). Among the adults, very few were on disability (4.2%), approximately one third was students, approximately one third was employed and approximately one third was both unemployed and not enrolled in school. They were mainly homozygous for the SCD genotype (82%), and most of them (86%) had been hospitalized at least once for VOC in the past 12 months. The use of analgesics at home was common (nearly 60% had used at least 3 different analgesics in the past 12 months), and SUD for analgesics other than EMONO was frequent (64%).

Concerning felt effects of EMONO, 38 patients (11%) experienced effects in the “Therapeutic only” category (analgesia, anxiolysis, sedation), 257 (76%) experienced a “Gliding” effect (plus or minus other effects) and 43 (13%) were classified in the “Others” category (33 citing effects that could be considered positive (well-being: 32 and reduction in negative affects: (1), and 11 undesirable effects (dizziness: 3, headache: 2, nausea/vomiting: 2, hallucinations: 1, excitement: 1, disorientation: 1, panic: 1).

Concerning sought effects of EMONO, almost all patients (99.7%) were looking for an analgesic effect, but 68% of patients were also looking for other effects. 129 (38%) were seeking “Therapeutic effects only”, 177 (53%) were looking for a “Gliding” effect and 30 (9%) were classified in the “Others” category (30 citations of well-being).

Due to missing data on SUD criteria, the primary outcome was evaluated in 335 patients (diagnosis of SUD, i.e., at least 2 SUD criteria for EMONO), and the secondary outcome was evaluated in 336 patients (at least one SUD criterion for EMONO). Figure 2 (Study population) details the number of patients included in the analyses.

Primary outcome: prevalence of SUD for EMONO

A total of 38 patients out of 335 (11.3% CI95% [8.0% to 14.7%]) had a SUD for EMONO (at least 2 criteria). Thirty-three (9.9%) had 2 or 3 criteria, which corresponded to a mild SUD according to DSM 5. Among them, only one patient used EMONO outside of a painful context.

The majority of patients (297; 88.9%) had no SUD for EMONO. Among them, 211 had no criterion for a SUD, and 86 patients (25.8%) had only one.

Table 1 Potential factors associated with the presence of at least one SUD criterion – univariate analysis

	All patients (N = 339) n (%) or m (SD)	No SUD criterion (N = 211) n (%) or m (SD)	At least one SUD criterion (N = 125) n (%) or m (SD)	p value
<i>Demographic data</i>				
Sex				
N	339	211	125	
Female	192 (56.6%)	110 (52.1%)	81 (64.8%)	0.02
Age (years)				
N	339	211	125	
Mean (SD)	20.2 (9.1)	20.1 (9.1)	20.3 (9.1)	0.81
Min–Max	[5.0;57.0]	[5.0;56.0]	[6.0;57.0]	
Under 18	147 (43.4%)	91 (43.1%)	55 (44.0%)	0.88
Over 18	192 (56.6%)	120 (56.9%)	70 (56.0%)	
<i>SCD clinical data and analgesics' use</i>				
Genotype				
N	338	210	125	
Homozygous SS	276 (81.7%)	170 (81.0%)	104 (83.2%)	0.09
Hospitalizations for VOC (past 12 months)				
N	339	211	125	
None	46 (13.6%)	37 (17.5%)	9 (7.2%)	0.006
1 or 2	158 (46.6%)	101 (47.9%)	55 (44.0%)	
3 or more	135 (39.8%)	73 (34.6%)	61 (48.8%)	
Number of analgesic treatments at home				
N	339	211	125	
≤ 2	140 (41.3%)	93 (44.1%)	46 (36.8%)	0.02
3	175 (51.6%)	109 (51.7%)	64 (51.2%)	
≥ 4	24 (7.1%)	9 (4.3%)	15 (12.0%)	
SUD for at least one analgesic drug (other than EMONO)				
N	333	209	121	
Yes	212 (63.7%)	119 (56.9%)	90 (74.4%)	0.002
<i>Use of psychoactive substances other than analgesics</i>				
Tobacco use				
N	261	161	97	
Yes	31 (11.9%)	21 (13.0%)	10 (10.3%)	0.51
Alcohol use				
N	261	161	97	
Yes	82 (31.4%)	54 (33.5%)	27 (27.8%)	0.34
Psychoactive medications (other than analgesics) use				
N	262	160	99	
Yes	43 (16.4%)	23 (14.4%)	19 (19.2%)	0.31
<i>Characteristics of EMONO use</i>				
Patients who felt analgesic effect				
N	339	211	125	
Yes	336 (99.1%)	210 (99.5%)	123 (98.4%)	0.56
Felt effects (categories*)				
N	338	211	125	
"Therapeutic only"	38 (11.2%)	33 (15.6%)	4 (3.2%)	0.002
"Gliding"	257 (76.0%)	150 (71.1%)	106 (84.8%)	
"Others"	43 (12.7%)	28 (13.3%)	15 (12.0%)	

Table 1 (continued)

	All patients (N = 339) n (%) or m (SD)	No SUD criterion (N = 211) n (%) or m (SD)	At least one SUD criterion (N = 125) n (%) or m (SD)	p value
Patients who sought analgesic effect				
N	339	211	125	
Yes	338 (99.7%)	210 (99.5%)	125 (100.0%)	1.00
Patients who sought other effects than analgesic				
N	339	211	125	
Yes	231 (68.1%)	134 (63.5%)	96 (76.8%)	0.01
Sought effects (categories*)				
N	337	210	125	
“Therapeutic only”	129 (38.3%)	90 (42.9%)	38 (30.4%)	0.02
“Gliding”	177 (52.5%)	98 (46.7%)	78 (62.4%)	
“Others”	31 (9.2%)	22 (10.5%)	9 (7.2%)	
Intake context				
N	337	210	124	
Not outside a painful context	336 (99.7%)	210 (100.0%)	123 (99.2%)	0.37

*The effects of EMONO were grouped into categories as follows:

“Therapeutic only” when the analgesic effect was the only or when it was associated with sedation and/or anxiolysis but with no other effect;

“Gliding” when “high” effects were mentioned regardless of other effects;

“Others” for patients who did not fit into either of the above two categories

Secondary outcomes

Characterization of patients with at least one SUD criterion for EMONO

According to Fig. 1, the more prevalent SUD criteria were item 6 (persistent usage despite persistent or recurrent social or interpersonal problems), positive in 15.3% of patients, item 1 (using more of a substance than planned, or using a substance for a longer interval than desired) in 14.8% and item 9 (persistent use despite the user’s awareness that the substance is causing or at least worsening a physical or mental problem) in 9.4%.

Factors associated with the presence of at least one SUD criterion

The results of univariate comparison between patients with at least one SUD criterion (125; 37.2%) for EMONO and patients with no criteria (211; 62.8%) are presented in Table 1. There was no significant difference in socio-economic status between patients with at least one SUD criterion and the others ($p=0.19$ for occupational activities in adults, $p=0.42$ for mother employment in minors, $p=0.28$ for father employment in minors).

In the final multivariate logistic regression model (Table 2), the independent risk factors associated with at least one SUD criterion were the feeling of effects different from the “Therapeutic only” ($OR=5.37$ for “Gliding” and $OR=3.99$ for “Others”), at least one hospitalization for VOC in the past 12 months ($OR=1.87$ for “one or

two” and $OR=2.79$ for “three or more”) and the presence of a SUD for at least one other analgesic drug ($OR=1.97$).

Discussion

N₂O, SCD and addiction: A false issue?

The results of our study showed that approximately 40% of the patients were treated with EMONO, and among them, only 11% had a SUD characterized, in the majority of cases, by only two positive criteria. Recent HAS recommendations [24] call for the safe use of analgesics, particularly opioids, in the management of pain to prevent any risk of misuse and addiction. One of the challenges is to make healthcare professionals aware of the need for early intervention in high-risk situations. In this attitude of early detection, we sought to identify the presence of at least one DSM criterion of SUD among EMONO users and to define the characteristics of the patients concerned (37%).

A higher SUD rate might have been expected. Indeed, SCD patients could be considered presenting addiction risk factors: they are young, in pain and receive recurrent psychotropic and analgesic treatments whose addictive nature is known, but 63% of patients did not present any criteria for SUD for EMONO.

The most frequently positive criteria for SUD were items 1 and 6, namely, “Using more of a substance than planned, or using a substance for a longer interval than desired” and “Persistent usage despite persistent or




Fig. 2 Study population

recurrent social or interpersonal problems”. In the context of EMONO use in hospitals, these criteria revealed situations of tension with medical staff during hospitalizations due to patient requests to obtain EMONO more frequently or to extend the time of administration.

In our study, certain characteristics seemed to be more present among patients presenting at least one SUD criterion for EMONO. First, they felt effects different from therapeutic effects more often, particularly effects that could be considered positive, such as “Gliding”, and therefore could be sought. Then, they were more likely to have severe SCD as they were hospitalized more often. Some authors have shown that SCD patients with extremely high hospital use demonstrated reactive behaviors in seeking care for pain management, which led to a distrustful and dysfunctional patient-provider relationship [25]. Moreover, according to univariate analysis, they used more analgesics at home and were more likely to have SUD for at least one other analgesic drug. No sociodemographic or socioeconomic data collected in the study were associated with presenting at least one SUD criterion for EMONO. Socioeconomic status is known to impact dependence in the general population [26]. It is possible that socioeconomic data collected in PHEDRE study were too limited even if they help to approximate socioeconomic status. To avoid extending the telephone questionnaire excessively and to enhance patient acceptance for the study, we chose to focus on specific variables: the consumption of analgesic medications, data related to patient care, and a few essential sociodemographic data. This decision was made to identify risk factors that we

Table 2 Multivariate logistic regression model—Risk factors for at least one SUD criterion for EMONO (N = 330; Hosmer–Lemeshow p value = 0.8825; AUC = 0.66 [0.61; 0.72])

Variables	Adjusted odds-ratio (OR)	CI _{95%}	p value
Felt effects (categories*)			0.0083
“Therapeutic only”	Reference	–	–
“Gliding”	5.37	[1.82; 15.83]	
“Others”	3.99	[1.15; 13.80]	
Hospitalizations for VOC (past 12 months)			0.0362
None	Reference	–	
1 or 2	1.87	[0.82; 4.26]	
3 or more	2.79	[1.22; 6.41]	
SUD for at least one analgesic drug other than EMONO	1.97	[1.18; 3.27]	0.0090

*The effects of EMONO were grouped into categories as follows:

“Therapeutic only” when the analgesic effect was the only or when it was associated with sedation and/or anxiolysis but with no other effect;

“Gliding” when “high” effects were mentioned regardless of other effects;

“Others” for patients who did not fit into either of the above two categories

could address, prevent, and make recommendations on, but they are not exhaustive.

No addiction with an addictive substance

Pharmacologically, N₂O acts on mediators involved in addictive phenomena, notably dopamine, a mediator of the reward circuit, opioidergic system and GABA, a mediator involved in anxiety. National addictovigilance monitoring has shown potential for abuse and dependence associated with significant daily consumption and harmful consequences, particularly neurological consequences [11]. Patients in the PHEDRE study also reported harmful consequences, as item 9 (persistent use despite the user's awareness that the substance is causing or at least worsening a physical or mental problem) was positive for 9% of patients. However, these consequences corresponded to unpleasant side effects such as "nausea" or "dizziness".

There are several possible explanations for the fact that there were few patients with SUD. First, as our results were based on declarative data in order to get as close as possible to actual patient consumption, but memorization bias and underreporting bias are possible. This risk of bias is one of the limitations of the study. If the patients questioned could not remember the details of their consumption, this was recorded as "missing data". Concerning use outside the context of pain and SUD criteria, it is possible that some respondents did not wish to admit to such misuse.

However, declarative data, despite the risk of bias inherent in this type of data, remains the closest to the reality of consumption by the person surveyed and Addictovigilance centres are used to carrying out studies on the use of psychoactive substances, and to collecting declarative data. To minimize declarative bias, the interviewer was not part of the patient medical team, and the data collected were not communicated to them. This was explained to the patient before starting the questionnaire, along with the fact that his or her answers would have no consequences in terms of therapeutic management. Second, in PHEDRE, it was not about diverted N₂O but EMONO, a drug subject in France to part of the regulations on narcotics. The low rate of use outside a painful context was predictable because EMONO is not widely available outside the hospital and therefore not easily accessible. This framework and the vigilance of health professionals allow the use to be controlled. However, patients may have requested EMONO during their hospitalization at times when they were in little or no pain, but only one patient was concerned about the use of EMONO at a time when he was not in pain. Above all, patients in the PHEDRE study used EMONO in an acute painful context, which may limit the addictive effects. Therefore, we were unable to compare the prevalence of

SUD criteria between intakes in a painful context and those outside a painful context.

Communicating for better pain management

Situations of tension between caregivers and patients for a probable undertreatment of pain could be related to the lack of knowledge of the characteristics of pain in these particular patients, especially in emergency services. However, no objective measure can assess pain in children and adults with SCD. Classic pain assessments are limited by the momentary assessment of pain and inter individual variability due to differences in pain tolerance [27]. For example, patients who suffer from chronic sickle cell pain may not have the typical physical characteristics of pain and may not appear distressed when performing daily activities [25]. Patients are therefore often confronted with an underestimation of the intensity of their pain by the caregivers. Thus, the rating on a pain intensity scale should never be the sole determinant for the administration of analgesia if it is questioned by the caregiver. The cornerstone of pain management is trust between the affected individual in pain and the health care provider [27]. Where there are sociocultural barriers (e.g., of class, race, ethnicity, language), the communication and assessment of pain can all be more compromised [28].

A better understanding of the concepts of addiction and pseudoaddiction would also help to better understand patients. In the case of repeated requests for analgesics, a precise evaluation must be proposed, including an addictological evaluation of all consumption and, in particular, the place of substances for the subject. Even if patients experience euphoric effects with EMONO and consequently can look for them, our results showed that what motivates the request is the analgesic effect. This is perhaps the main contribution of PHEDRE. The repeated requests for EMONO are also related to the pharmacology of N₂O, which has a very short-lived effect. Sickle cell pain is said to be worse than postoperative or traumatic pain and is as intense as metastatic bone cancer pain [29, 30]. EMONO is often the first medication administered upon arrival at the hospital to relieve pain, particularly in children [14], inducing a high level of patient expectation for this drug. The memory of previous administrations and the instantaneous effect of EMONO with immediate pain relief, compared to other analgesic therapies with a longer delay of action, could explain the positive effects felt and sought by patients.

Conclusions

PHEDRE was a large study conducted among SCD patients, that explored SUD for EMONO among these chronic pain patients, which are not comparable to other

chronic pain patients. To our knowledge, this exploration has never been carried out elsewhere.

Our results showed that the use of EMONO was not problematic for the majority of patients, which should prompt a change in the modalities of pain management and the reinforcement of psychological care. Manifestations of SUD that led to tensions with healthcare teams should alert and lead to an evaluation to distinguish a true addiction from a pseudoaddiction. If genuine drug addiction to analgesics was identified, it would require treatment adjustment.

Acknowledgements

We thank the French health products agency (Agence Nationale de Sécurité du Médicament et des produits de santé – ANSM) that funded the project (AAP-2014-009). We wish to sincerely thank all the medical practitioners of PHEDRE group who accepted to participate in the study, for the kindness with which they received the project and for their investment in recruiting patients: Christelle CHANTALAT (AP-HP Kremlin-Bicêtre), Françoise DRISS (AP-HP Kremlin-Bicêtre), Corinne GUITTON (AP-HP Kremlin-Bicêtre), Karima DEBBACHE (AP-HP Henri Mondor), Elena FOÏS (AP-HP Henri Mondor), Frédéric GALACTEROS (AP-HP Henri Mondor), Anoosha HABIBI (AP-HP Henri Mondor), Anne LEON (AP-HP Tenon), Sarah MATTIONI (AP-HP Tenon), Aline SANTIN (AP-HP Tenon), Scylia ALEXIS-FARDINI (CHU de Pointe-à-Pitre), Edima AUGUSTY (CHU de Pointe-à-Pitre), Marie BILLAUD (CHU de Pointe-à-Pitre), Lydia DIVALLE-DOUMDO (CHU de Pointe-à-Pitre), Maryse ETIENNE-JULAN (CHU de Pointe-à-Pitre), Nathalie LEMONNE (CHU de Pointe-à-Pitre), Marie PETRAS (CHU de Pointe-à-Pitre), Cécile ARNAUD (CHIC Créteil), Annie KAMDEM (CHIC Créteil), Corinne PONDARRE (CHIC Créteil), Amélie PASSERON (AP-HP George Pompidou), Christian ROSE (GHICL), Pierre MORNAND (AP-HP Trousseau), Assa NIAKATE (AP-HP Trousseau), Marie-Hélène ODIEVRE (AP-HP Trousseau), Cécile DUMESNIL (CHU de Rouen), Agnès LAHARY (CHU de Rouen), Stéphanie NGO (CHU de Rouen), Line HAUSTANT-ANDRY (CH du Lamentin), Romana IFRIM (CH du Lamentin), Gylna LOKO (CH du Lamentin), Marie-Laure COUEC (CHU de Nantes), Agathe MASSEAU (CHU de Nantes), Violaine NOEL (CHU de Reims), Claire PLUCHART (CHU de Reims), Shanti AME (CHRU de Strasbourg), Catherine PAILLARD (CHRU de Strasbourg), Abdourahim CHAMOUINE (CH de Mayotte), Alain GAROU (CH de Mayotte), Marie-Rita ANDREU (CHU d'Angers), Jean-François BRASME (CHU d'Angers), Martine GARDEMBAS (CHU d'Angers), Marie-Catherine RECEVEUR (CHU de Bordeaux), Camille RUNEL-BELLIARD (CHU de Bordeaux), Odile LEJARS (CHU de Tours), Jean-Baptiste VALENTIN (CHU de Tours), Corinne ARMARI (CHU de Grenoble), Caroline MAKOWSKI (CHU de Grenoble), Pierre COUGOUL (IUCT-Oncopôle), Anne BESANCON (CH Le Mans), Habib GHNAYA (CH Le Mans), Vanina GIACCOBBI (CH Le Mans), Aurélie GRADOS (APHM), Estelle JEAN (APHM), Isabelle THURET (APHM), Marie-Françoise BARRAULT-ANSTETT (CH d'Orléans), Mohamed CONDE (CH d'Orléans), Suzanne N'DIZEYE (CH d'Orléans), Laurent HOLVOET (AP-HP Robert Debré), Guillaume GONDRAN (CHU de Limoges), Christophe PIGUET (CHU de Limoges), Marie-Pierre CASTEX (CHU de Toulouse), Ana BERCEANU (CHU de Besançon), Pauline SIMON (CHU de Besançon), Wadih ABOUCHAHLA (CHRU de Lille), Anne LAMBILLIOTTE (CHRU de Lille), Giovanna CANNAS (CHU de Lyon), Alexandra GAUTHIER (CHU de Lyon), Solène POUTREL (CHU de Lyon), Fabrice MONPOUX (CHU de Nice), Pierre Simon ROHRICH (CHU de Nice), Audrey BARRELET (CH de Saint-Laurent du Maroni), Jérôme CLOUZEAU (CH de Saint-Laurent du Maroni), Adeline MALLARD (CH de Saint-Laurent du Maroni), Valérie LI THIAO TE (CHU d'Amiens), Lavinia MERLUSCA (CHU d'Amiens), Etienne MERLIN (CHU de Clermont-Ferrand), Marc RUIVARD (CHU de Clermont-Ferrand), Damien BODET (CHU de Caen), Hyacinthe JOHNSON (CHU de Caen), Odile MINCKES (CHU de Caen), Elodie COLOMB-BOTTOLIER (CHU de Dijon), Tackwa KHALIFEH (CHU de Poitiers), Alain RAMASSAMY (CHU de Poitiers), Stanislas NIMUBONA (CHU de Rennes), Fabienne TOUTAIN (CHU de Rennes), Arnaud BOUTET (CH de Saint-Nazaire), Julie GRAVELEAU (CH de Saint-Nazaire), Samir HARCHAOUI (CHG de Lisieux), Muriel LALANDE (CHU de Montpellier), Robert NAVARRO (CHU de Montpellier), Aurélie DESBREE (CHU de Saint-Etienne), Isabelle GUICHARD (CHU de Saint-Etienne), Liana CARAUSU (CHU de Brest), Jean-Richard EVEILLARD (CHU de Brest), Julie MACHIN (CH de Roubaix), Marie-Hélène PIERRE (CH de Roubaix), Diane CERUTTI (CH

intercommunal de Toulon), Narcisse ELENGA (CH de Cayenne). We would like to thank all patients for their participation in the study and for sharing a little bit of their daily life with us. We would like to thank all the members of the steering committee who participated in the construction of this ambitious project: Marie-Laure Couec, Agathe Masseau, Marie-Hélène Drouineau, Marie Grall-Bronnec, Olivier Bonnot, Nicolas Authier, Sylvie Deheul, Anne Roussin, Joëlle Micallef, Samira Djezzar, Fanny Feuillet, Morgane Rousselet, Caroline Victorri-Vigneau and Marie Gérardin. Finally, we would like to thank the members of FAN for their help in setting up this study: Nicolas Authier (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Clermont-Ferrand), Alexandra Boucher (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Lyon), Anne-Sylvie Caous and Sylvie Deheul (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Lille), Amélie Daveluy (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Bordeaux), Samira Djezzar (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Paris), Nathalie Fouilhé (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Grenoble), Valérie Gibaja (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Nancy), Reynald Le Boisselier (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Caen), Joëlle Micallef (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Marseille), Stéphanie Pain (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Poitiers), Hélène Peyrière (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Montpellier), Anne Roussin (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Toulouse) and Caroline Victorri-Vigneau (Centre d'Evaluation et d'Information sur la Pharmacodépendance—Addictovigilance de Nantes).

Author contributions

MGe is responsible for the project management. She contributed to the questionnaire development and wrote the first draft of the manuscript. MR contributed to the questionnaire development and participated in the setting-up of the study in the different centres. MLC contributed to design the study. She provided her expertise in the area of sickle-cell disease in paediatric patients and included patients in the study. AM contributed to design the study. She provided her expertise in the area of sickle-cell disease in adult patients and included patients in the study. The PHEDRE group included patients in the study. AA read and approved the manuscript. NA, SDe, AR, JM and SDJ were members of the multi-disciplinary steering committee; they contributed to the setting-up of the study in their respective geographic areas with the support of the FAN. The FAN helped in setting up this study. FF provided methodological advice, designed the statistical analysis plan and conducted the statistical analysis. PJ read and approved the protocol. MGB contributed to design the study. She provided her expertise in the area of addictology. CVV designed the study and finalized the protocol. All authors read and approved the manuscript.

Funding

For this project, the University Hospital of Nantes has received funding only from the French health products agency (Agence Nationale de Sécurité du Médicament et des produits de santé – ANSM).

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request. We are urged to be cautious by our Hospital Clinical Research Department regarding the transmission of anonymized data. Moreover, the data collected in this study may include potentially sensitive data (concerning mental health and behavior). Finally, before sending data to other researchers, we must determine that the purpose of the data processing is compatible with the information provided to and consent given by the patients and legal representatives for patients under 18 years old.

Declarations

Ethics approval and consent to participate

This study was approved by the CCTIRS (Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé) on

11 March 2015, the CNIL (Commission Nationale de l'Informatique et des Libertés) on 11 June 2015 and the GNEDS (Groupe Nantais d'Éthique dans le Domaine de la Santé) on 3 March 2015. All participants received an information leaflet for their age range (as do the parents of minors) and provided written informed consent in accordance with the Declaration of Helsinki. For minors, parents also signed a consent form authorizing their children's participation. The study is registered as ClinicalTrials.gov ID: NCT02580565.

Consent for publication

Not applicable.

Competing interests

Authors declare that they have no competing interest.

Author details

¹CHU Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, Nantes Université, 9 Quai Moncousu, 44 093 Nantes Cedex 1, France. ²CHU Nantes, UIC Psychiatrie et Santé Mentale, Nantes Université, Nantes, France. ³CHU Nantes, CHU Tours, INSERM, MethodS in Patients Centered Outcomes and HHealth ResEarch, SPHERE, Nantes Université, Tours Université, Nantes, France. ⁴CHU Nantes, Service de Pédiatrie et d'Oncologie Pédiatrique, Nantes Université, Nantes, France. ⁵CHU Nantes, Service de Médecine Interne, Nantes Université, Nantes, France. ⁶PHEDRE investigateurs, PHEDRE protocole de recherche, Nantes, France. ⁷CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Clermont Auvergne Université, Clermont-Ferrand, France. ⁸CHU Lille, Service de Pharmacologie, Lille Université, Lille, France. ⁹CHU Toulouse, Service de Pharmacologie Médicale et Clinique, Toulouse Université, Toulouse, France. ¹⁰APHM, Service de Pharmacologie Clinique, Hôpital de La Timone, Institut de Neurosciences Des Systèmes, Aix-Marseille Université, Marseille, France. ¹¹APHP Paris, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance de Paris, Hôpital Fernand Widal, APHP Paris, Paris, France. ¹²French Addictovigilance Network, FAN, Nantes, France. ¹³CHU Nantes, DRI, Plateforme de Méthodologie et Biostatistique, Nantes Université, Nantes, France.

Received: 24 November 2023 Accepted: 3 March 2024

Published online: 18 March 2024

References

- Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. *Anesth Prog*. 2007;54(1):9–18.
- Fidalgo M, Prud'homme T, Allio A, Bronnec M, Bulteau S, Joliet P, et al. Nitrous oxide: What do we know about its use disorder potential? Results of the French Monitoring Centre for Addiction network survey and literature review. *Subst Abuse*. 2019;40(1):33–42.
- Gillman MA. Nitrous oxide, an opioid addictive agent. Review of the evidence. *Am J Med*. 1986;81(1):97–102.
- Richardson PG. Peripheral neuropathy following nitrous oxide abuse. *Emerg Med Australas EMA*. 2010;22(1):88–90.
- Kaar SJ, Ferris J, Waldron J, Devaney M, Ramsey J, Winstock AR. Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. *J Psychopharmacol Oxf Engl*. 2016;30(4):395–401.
- van Amsterdam J, Nabben T, van den Brink W. Recreational nitrous oxide use: Prevalence and risks. *Regul Toxicol Pharmacol RTP*. 2015;73(3):790–6.
- Randhawa G, Bodenham A. The increasing recreational use of nitrous oxide: history revisited. *Br J Anaesth*. 2016;116(3):321–4.
- Cousaert C, Heylens G, Audenaert K. Laughing gas abuse is no joke. An overview of the implications for psychiatric practice. *Clin Neurol Neurosurg*. 2013;115(7):859–62.
- Alt RS, Morrissey RP, Gang MA, Hoffman RS, Schaumburg HH. Severe myeloneuropathy from acute high-dose nitrous oxide (N₂O) abuse. *J Emerg Med*. 2011;41(4):378–80.
- Forrester MB. Nitrous oxide misuse reported to two United States data systems during 2000–2019. *J Addict Dis*. 2021;39(1):46–53.
- ANSM : Agence nationale de sécurité du médicament et des produits de santé. Compte rendu CT 17 mai 2018.pdf [Internet]. [cited 2023 Nov 21]. Available from: https://archive.ansm.sante.fr/var/ansm_site/storage/original/application/ce88e158f1d0a7427961adc5d9bc54b.pdf
- Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geo-statistical model-based map and population estimates. *Lancet Lond Engl*. 2013;381(9861):142–51.
- Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet Lond Engl*. 2010;376(9757):2018–31.
- Haute Autorité de Santé (HAS). Syndromes drépanocytaires majeurs de l'enfant et de l'adolescent Protocole national de diagnostic et de soins pour une maladie rare. Guide Médecin Affection Longue Durée. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2010-04/ald_10_pnds_drepano_enfant_web.pdf
- Haute Autorité de Santé (HAS). Syndromes drépanocytaires majeurs de l'adulte Protocole national de diagnostic et de soins pour une maladie rare - guide - affection de longue durée, janvier 2010. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2010-04/ald_10_guide_drepano_adulte_web.pdf
- Angoulvant F, Redant S, Holvoet L, Millet B, Ferster A, Andreu-Gallien J. Prise en charge de la douleur des enfants drépanocytaires aux urgences: recommandations et état des lieux dans le Réseau Mère-Enfant de la francophonie. *Réanimation*. 2011;20(6):516–24.
- Dydyk AM, Sizemore DC, Haddad LM, Lindsay L, Porter BR. NP Safe Prescribing Of Controlled Substances While Avoiding Drug Diversion. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK564518/>
- Weissman DE, Haddox JD. Opioid pseudoaddiction—an iatrogenic syndrome. *Pain*. 1989;36(3):363–6.
- Elander J, Lusher J, Bevan D, Telfer P. Pain management and symptoms of substance dependence among patients with sickle cell disease. *Soc Sci Med*. 2003;57(9):1683–96.
- Lusher J, Elander J, Bevan D, Telfer P, Burton B. Analgesic addiction and pseudoaddiction in painful chronic illness. *Clin J Pain*. 2006;22(3):316–24.
- Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. *J Pain Symptom Manage*. 2004;27(2):156–69.
- Gérardin M, Couec ML, Grall-Bronnec M, Feuillet F, Wainstein L, Rousselet M, et al. PHEDRE trial protocol—observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population. *BMC Psychiatry*. 2015;14(15):281.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM–5) [Internet]. 5th edition. Available from: <https://www.psychiatry.org/psychiatrists/practice/dsm>
- Haute Autorité de Santé (HAS). Haute Autorité de Santé. Bon usage des médicaments opioïdes : antalgie, prévention et prise en charge du trouble de l'usage et des surdoses. Available from: https://www.has-sante.fr/jcms/p_3215131/fr/bon-usage-des-medicaments-opioides-antalgie-prevention-et-prise-en-charge-du-trouble-de-l-usage-et-des-surdoses
- Brown SE, Weisberg DF, Balf-Soran G, Sledge WH. Sickle cell disease patients with and without extremely high hospital use: pain, opioids, and coping. *J Pain Symptom Manage*. 2015;49(3):539–47.
- Reynaud M, Karila L, Aubin HJ, Benyamina A. Traitement d'addictologie [Internet]. Cachan: Lavoisier; 2016. 928 p. (Traité; vol. 2e éd.). Available from: <https://www.cairn.info/traitement-d-addictologie--9782257206503.htm>
- Brandow AM, DeBaun MR. Key components of pain management for children and adults with sickle cell disease. *Hematol Oncol Clin North Am*. 2018;32(3):535–50.
- Wright K, Adeosun O. Barriers to effective pain management in sickle cell disease. *Br J Nurs Mark Allen Publ*. 2009;18(3):158–61.
- Jenerette C, Leak A. The role of oncology nurses in the care of adults with sickle cell disease. *Clin J Oncol Nurs*. 2012;16(6):633–5.
- Wilkie DJ, Molokie R, Boyd-Seal D, Suarez ML, Kim YO, Zong S, et al. Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease. *J Natl Med Assoc*. 2010;102(1):18–27.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.